Overview

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.

Phase:

Phase 2

Details

Lead Sponsor:

RXi Pharmaceuticals, Corp.